Results 141 to 150 of about 5,550 (180)

The JAK2 ^V617F mutation and thrombosis

British Journal of Haematology, 2008
Summary Since the discovery of the JAK2 V617F mutation, the clinical and pathological consequences of this acquired defect have been extensively investigated to determine whether its presence characterises a distinct subgroup of myeloproliferative ...
S K, Austin, J R, Lambert
openaire   +2 more sources

JAK2 V617F Mutation in Essential Thrombocythemia.

Blood, 2006
Abstract Background: Essential thrombocythemia (ET) is thought to reflect transformation of a multipotent hematopoietic stem cell, but its molecular pathogenesis has remained obscure. But tyrosine kinase, especially Janus kinase 2 (JAK2) has been implicated in myeloproliferative disorders other than chronic myeloid leukemia.
Soo-Mee Bang, Soo-Jin Yoo, Jae-Hoon Lee, Dong-Bok Shin, Yiel Hea Seo, Pil Whan Park, Jeong Yeal Ahn   +6 more
openaire   +1 more source

JAK2 V617F mutation is absent in chronic lymphocytic leukemia

Leukemia & Lymphoma, 2006
The expansion of leukemic clone in B-chronic lymphocytic leukemia (CLL) has been related to signals from the micro-environment that influence the balance between anti-apoptotic and pro-apoptotic si...
Stéphanie, Poulain, Maud, Merchez, Agnès, Daudignon, Marc, Simon, Patrick, Duthilleul, Pierre, Morel   +5 more
openaire   +2 more sources

Is the JAK2 V617F Mutation a Hallmark for Different Forms of Thrombosis?

Acta Haematologica, 2010
<i>Background/Aims:</i> The association between venous thrombosis outside the splanchnic area as well arterial thromboembolism and the JAK2 V617F mutation, an important marker for chronic myeloproliferative neoplasms (MPN), is not completely clear.
Katja, Zerjavic, Boris, Zagradisnik, Spela, Stangler Herodez, Lidija, Lokar, Marjana, Glaser Krasevac, Nadja, Kokalj Vokac   +5 more
openaire   +2 more sources

JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome

Human Pathology, 2010
The 3q21q26 syndrome is recognized as a distinct clinicopathologic entity. Patients have a myeloid neoplasm associated with 3q21q26 cytogenetic abnormalities and present with anemia, leukopenia, and either thrombocytosis or a normal platelet count associated with dysplasia.
Pei, Lin, Rajyalakshmi, Luthra, Roberto H, Nussenzveig, L Jeffrey, Medeiros   +3 more
openaire   +2 more sources

Occurrence of the JAK2 V617F mutation in the Budd–Chiari syndrome

Blood Coagulation & Fibrinolysis, 2008
Myeloproliferative diseases represent a major risk factor for Budd-Chiari syndrome. In 32 patients with Budd-Chiari syndrome, the JAK2 V617F mutation was detected, in heterozygous state, in 11 individuals (34.4%; 95% confidence interval: 18.6-53.2). Eight patients with (72.7%; 95% confidence interval: 39.0-94.0) and six without (28.6%; 95% confidence ...
COLAIZZO D., AMITRANO L., TISCIA G. L., IANNACCONE L., GRANDONE E., GUARDASCIONE M. A., GALLONE, ANNA, MARGAGLIONE, MAURIZIO   +7 more
openaire   +2 more sources

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Blood, 2006
Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)-based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those ...
Campbell, Peter J, Griesshammer, Martin, Döhner, Konstanze, Döhner, Hartmut, Kusec, Rajko, Hasselbalch, Hans C, Larsen, Thomas Stauffer, Pallisgaard, Niels, Giraudier, Stéphane, Le Bousse-Kerdilès, Marie-Caroline, Desterke, Christophe, Guerton, Bernadette, Dupriez, Brigitte, Bordessoule, Dominique, Fenaux, Pierre, Kiladjian, Jean-Jacques, Viallard, Jean-François, Brière, Jean, Harrison, Claire N, Green, Anthony R, Reilly, John T   +20 more
openaire   +3 more sources

Absence of FLT3 and JAK2 (V617F) Mutations in Langerhans Cell Histiocytosis

Blood, 2008
Abstract Langerhans cell histocytosis (LCH) is a neoplasm of histiocytic cells believed to be derived from cells of the dendritic system, but the disease pathogenesis is unknown. FMS-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that is expressed on the surface of hematopoietic stem cells and plays an important ...
Malak, Abedalthagafi, Huimin, Guo, Dan-Paul, Hartmann, Metin, Ozdemirli   +3 more
openaire   +2 more sources

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

Blood, 2008
AbstractWe studied the lineage distribution of JAK2 mutations in peripheral blood of 8 polycythemia vera (PV) patients with exon 12 mutations and in 21 PV patients with JAK2-V617F. Using a quantitative allele discrimination assay, we detected exon 12 mutations in purified granulocytes, monocytes, and platelets of 8 patients studied, but lymphoid cells ...
Li, Sai, Kralovics, Robert, De Libero, Gennaro, Theocharides, Alexandre, Gisslinger, Heinz, Skoda, Radek C.   +5 more
openaire   +4 more sources

JAK2 (V617F) Mutation and Cerebral Venous Thrombosis,

Blood, 2011
Abstract Abstract 3339 Background. Whether or not cerebral venous thrombosis, such as splanchnic venous thrombosis, can be the first manifestation of an underlying myeloproliferative neoplasm is currently unclear. Methods.
Ida Martinelli, Serena Maria Passamonti, Eugenia Biguzzi, Franca Franchi, Francesca Gianniello, Paolo Bucciarelli, Daniela Pietra, Pier Mannuccio Mannucci, Mario Cazzola   +8 more
openaire   +1 more source